Korea Investment Corp
NBIX icon

Korea Investment Corp’s Neurocrine Biosciences NBIX Stock Holding History

Korea Investment Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.2M Buy
172,989
+102,400
+145% +$15.2M 0.06% 296
2026
Q1 		$9.3M Sell
70,589
-18,000
-20% -$2.39M 0.02% 535
2025
Q4 		$12.6M Buy
88,589
+16,900
+24% +$2.45M 0.02% 469
2025
Q3 		$10.1M Buy
71,689
+34,800
+94% +$4.72M 0.02% 491
2025
Q2 		$4.64M Sell
36,889
-50,100
-58% -$5.75M 0.01% 615
2025
Q1 		$9.62M Buy
86,989
+25,900
+42% +$3.28M 0.02% 515
2024
Q4 		$8.34M Sell
61,089
-5,100
-8% -$631K 0.02% 555
2024
Q3 		$7.63M Sell
66,189
-41,288
-38% -$5.66M 0.02% 523
2024
Q2 		$14.8M Buy
107,477
+69,372
+182% +$9.51M 0.04% 387
2024
Q1 		$5.26M Sell
38,105
-45,324
-54% -$6.19M 0.01% 569
2023
Q4 		$11M Buy
83,429
+48,280
+137% +$5.56M 0.03% 443
2023
Q3 		$3.95M Buy
35,149
+19,768
+129% +$2.08M 0.01% 546
2023
Q2 		$1.45M Sell
15,381
-1,165
-7% -$114K ﹤0.01% 692
2023
Q1 		$1.67M Sell
16,546
-1,879
-10% -$196K ﹤0.01% 687
2022
Q4 		$2.2M Buy
18,425
+3,186
+21% +$373K 0.01% 679
2022
Q3 		$1.62M Buy
15,239
+8,099
+113% +$822K 0.01% 692
2022
Q2 		$696K Buy
+7,140
New +$659K ﹤0.01% 727
2021
Q3 		– Sell
-2,200
Closed -$214K – 743
2021
Q2 		$214K Sell
2,200
-200
-8% -$19.2K ﹤0.01% 737
2021
Q1 		$233K Sell
2,400
-23,500
-91% -$2.46M ﹤0.01% 710
2020
Q4 		$2.48M Buy
25,900
+1,600
+7% +$155K 0.01% 633
2020
Q3 		$2.34M Buy
24,300
+1,000
+4% +$116K 0.01% 575
2020
Q2 		$2.84M Buy
23,300
+1,400
+6% +$155K 0.01% 539
2020
Q1 		$1.9M Buy
+21,900
New +$2.14M 0.01% 575

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Korea Investment Corp's NBIX Position: Q2 2026 in Review

Korea Investment Corp increased its Neurocrine Biosciences (NBIX) stake by 145% in Q2 2026, buying an estimated $15.2M and bringing the position to 172,989 shares worth $29.2M. The position accounts for 0.06% of the portfolio, ranked #296.

Korea Investment Corp first reported a position in NBIX in Q1 2020 and has held it in 23 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Korea Investment Corp held 172,989 shares of Neurocrine Biosciences worth $29.2M as of Q2 2026.
  • Korea Investment Corp bought 102,400 Neurocrine Biosciences shares in Q2 2026, an estimated $15.2M.
  • Neurocrine Biosciences made up 0.06% of Korea Investment Corp's portfolio in Q2 2026, its #296 holding.
  • Korea Investment Corp first reported a position in Neurocrine Biosciences in Q1 2020 and has held it in 23 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Korea Investment Corp's 13F filing for Q2 2026, filed 12 Aug 2026.